

1 From a single host to global spread: The global 2 mobility based modelling of the COVID-19 pandemic 3 implies higher infection rate and lower detection ratio 4 than current estimates.

5 Marian Siwiak PhD 1, Pawel Szczesny PhD 1, Marlena Siwiak PhD 1
6 1 Data 3.0, Sevenoaks, TN14 7TG, UK
7 Corresponding Author:
8 Marian P. Siwiak PhD 1
9 3 Forge Way, Sevenoaks, TN14 7TG, United Kingdom
10 Email address: siwiak@data30.co.uk

11 Abstract

12 Background

13 Since the outbreak of the COVID-19 pandemic, multiple efforts of modelling of the geo-
14 temporal transmissibility of the virus have been undertaken, but none describes the pandemic
15 spread at the global level. The aim of this research is to provide a high-resolution global model
16 of the pandemic that overcomes the problem of biased country-level data on the number of
17 infected cases. To achieve this we propose a novel SIR-type metapopulation transmission model
18 and a set of analytically derived model parameters. We used them to perform a simulation of the
19 disease spread with help of the Global Epidemic and Mobility (GLEAM) framework embedding
20 actual population densities, commute patterns and long-range travel networks. The simulation
21 starts on Nov 17th, 2019 with just a single pre-symptomatic, yet infectious, case in Wuhan,
22 China, and results in an accurate prediction of the number of diagnosed cases after 154 days in
23 multiple countries across five continents. In addition, the model outcome shows high compliance
24 with the results of a random screening test conducted on pregnant women in the New York area.

25 Methods

26 We have built a modified SIR metapopulation transmission model and parameterized it
27 analytically either by setting the values of the parameters based on the literature, or by assuming
28 their plausible values. We compared our results with the number of diagnosed cases in twenty
29 selected countries which provide reliable statistics but differ substantially in terms of strength
30 and speed of undertaken Non-Drug Interventions. The obtained 95% confidence intervals for the
31 predictions are in agreement with the empirical data.

32 Results

33 The parameters that successfully model the pandemic are: the basic reproduction number R_0 , 4.4;
34 a latent non-infectious period of 1.1. days followed by 4.6 days of the presymptomatic infectious
35 period; the probability of developing severe symptoms, 0.01; the probability of being diagnosed
36 when presenting severe symptoms of 0.6; the probability of diagnosis for cases with mild
37 symptoms or asymptomatic, 0.001.

38 Discussion

39 Parameters that successfully reproduce the observed number of cases indicate that both R_0 and
40 the prevalence of the virus might be underestimated. This is in concordance with the newest
41 research on undocumented COVID-19 cases. Consequently, the actual mortality rate is
42 putatively lower than estimated. Confirmation of the pandemic characteristic by further
43 refinement of the model and screening tests is crucial for developing an effective strategy for the
44 global epidemiological crisis.

45 Introduction

46 As of April 23rd, 2020, novel coronavirus SARS-CoV-2 has already spread into 185 countries
47 and territories around the world (Dong, Du & Gardner, 2020). With over two and half a million
48 confirmed infections and over 180 thousand deaths (Dong, Du & Gardner, 2020), it became a
49 global challenge. COVID-19, the disease caused by this coronavirus, was characterised as a
50 pandemic by WHO on March 11th, 2020.

51 While several different measures to contain the virus have been implemented by countries all
52 over the world, their effectiveness remains to be seen. Until an effective treatment is available,
53 the accuracy of the pandemic models and the decisions made on their basis are the major factors
54 in reducing the overall mortality in the COVID-19 pandemic.

55 The models used to inform decision-makers differ significantly in their basic assumptions
56 because it is the first coronavirus of such an impact in terms of the number of fatal cases.
57 Moreover, the existing modelling approaches often use biased data for tuning parameters or
58 assessing models' quality. In particular, most models use country-level data which is biased by
59 one or many of the following factors: (i) level of transparency in acquiring, analysing,
60 interpreting and reporting of data, (ii) level of detection effort, (iii) efficiency of introduced Non-
61 Drug Interventions, (iv) biased sampling of people to be tested (individuals showing severe and
62 typical symptoms or suspected of having a contact with an infected person are more likely to be
63 tested). The bias in data could be avoided by conducting well designed, random screening tests,
64 but so far just a few such attempts have been made and they were limited to small and isolated
65 communities in Italy (Lavezzo et al., 2020), and Germany (Streeck et al., 2020), or women
66 admitted for delivery (Sutton et al., 2020).

67 Also, as of the date of submitting this work, there were no peer-reviewed geo-temporal models
68 of the pandemic. We argue that creating a global model by fitting curves to observed data is
69 impossible, unless the data used in this exercise is a result of large scale screening tests. As
70 mentioned above, country-level data is biased and the nature of this bias is different for each
71 country, mainly reflecting state policy towards the disease. Obviously, fitting model curves on
72 global data bears a significant error, as this data is a mixture of all country-level biases.

73 Even the proper characteristic of the virus is hampered by the above-mentioned biases. For
74 instance, early estimates of the basic reproduction number of the virus, R_0 , were typically
75 obtained using only Chinese data on the number of diagnosed cases (Zhang et al., 2020; Wu,
76 Leung & Leung, 2020; Liu et al., 2020). These estimates proposed the value of R_0 within the
77 range 1.5-6.47, and the earliest most likely served as the basis for the January's official WHO
78 estimate, which stated $R_0=1.4-2.5$ ("Statement on the meeting of the International Health
79 Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus 2019 (n-
80 CoV) on 23 January 2020"). However, re-analysis of Chinese data provided an updated estimate
81 of 5.7 (95% CI 3.8-8.9) (Steven Sanche et al., 2020).

82 Similar problems arise when estimating the actual prevalence of the virus. In this case, the
83 estimates are not only biased by the state policy, but also by the fact that many infections are
84 mild, asymptomatic or with atypical symptoms. In fact, many COVID-19 cases pass unnoticed,
85 for instance in Li's and coworkers China study, over 50% (Li et al., 2020a).

86 The main objective of this research is to create a global model of the early stages of the
87 pandemic that would overcome the problem of the biased data on the number of infected cases.
88 This goal was achieved by creating a first global model of the COVID-19 pandemic that builds
89 on top of the successful modelling framework GLEAM (Van den Broeck et al., 2011). In
90 contrast to many existing models, our attempt did not use biased country-level data on the
91 number of infected cases to fit the model curve. Instead, it used a set of predefined parameters to
92 simulate the spread of the disease around the world starting from a single infected host in
93 Wuhan, China on Nov 17th, 2019. The exact date was suggested by unverified press reports and
94 used widely as a date of a disease contraction for "patient zero", but evolutionary tracing also
95 suggests a similar timepoint (Li et al., 2020b). The simulation took into account the current
96 population densities all over the world, actual commute and flight networks, and travel ability of
97 infected individuals. The simulation was run with 20 iterations for 154 days till Apr 19th, 2020.
98 The obtained results were used to create 95% confidence intervals for curves of cumulative
99 number of diagnosed cases, separately for each country in the world.

100 To assess the quality of our model, its results should be compared to the observed data on the
101 number of diagnosed cases, but this data suffers from four biases, listed above. These biases
102 cannot be totally eliminated, but careful selection of countries used in the analysis may reduce
103 their impact significantly. In particular, we limited the analysis of model results to twenty
104 countries which to our belief provide the most accurate and transparent reports on the number of
105 infected cases (reducing bias nr 1). Selected countries are also divergent in terms of their
106 detection efforts illustrated by the number of conducted tests per capita (reducing bias nr 2).
107 Additionally, our model depicts the early stages of the pandemic when Non-Drug Interventions
108 were not yet introduced on a large scale in the selected countries, and if they were, the exact time
109 of intervention was added to the final diagrams to show its impact on the number of diagnosed
110 cases (reducing bias nr 3). Furthermore, the proportion of symptomatic versus mild and
111 asymptomatic cases is built in the model, so is the fact that symptomatic individuals are more
112 likely to be tested (reducing bias nr 4). Finally, the detectability of the disease is also built in the
113 model. This means that the presented confidence intervals depict the plausible range of
114 diagnosed cases assuming a given detectability, not the actual number of infected individuals in
115 the country. However, the latter may easily be assessed knowing the assumed detectability, or
116 derived from the model file provided with this paper.

117 The presented model enables better understanding of the virus, its infectivity and detectability.
118 Also, it may serve as a solid foundation for further attempts of global and country-level
119 modelling. In particular, more detailed models that include information on introduced
120 precautions may be created by making the detectability parameter variable in time and
121 geographics. This would enable an optimal pandemic strategy to be established for each country.

122 **Materials & Methods**

123 **Modelling software**

124 The model is based on the Global Epidemic and Mobility Model (GLEAM) framework (Balcan
125 et al., 2010), implemented in the GLEAMviz software (Van den Broeck et al., 2011). The
126 GLEAM model integrates sociodemographic and population mobility data in a spatially
127 structured stochastic disease approach to simulate the spread of epidemics at a worldwide scale.
128 It was previously used for a real-time numerical forecast of the global spreading of Influenza
129 A/H1N1 (Tizzoni et al., 2012), and the accuracy of that modelling was later confirmed (Tizzoni
130 et al., 2012).

131 **Data sources**

132 The reference data about the number of SARS-CoV-2 diagnosed patients in the period from Jan
133 22, 2020, to Apr 19th, 2020, were downloaded from the Johns Hopkins University of Medicine
134 Coronavirus Resource Center GitHub repository <https://github.com/CSSEGISandData/COVID-19>.
135 The provided data have been grouped by country. These data sources were used to assess the
136 quality of the model results. Empirical data for the time preceding Jan 22nd, 2020 is not available
137 in the cited source.

138 Information about the severity of developed symptoms was derived from the worldometer.info
139 website <https://www.worldometers.info/coronavirus/>.

140 Information on testing efforts in selected countries, comes from the
141 <https://ourworldindata.org/coronavirus-testing-source-data> website.

142 Approximation of the number of mild and asymptomatic cases in the New York area was derived
143 from the results of a random screening test performed on women admitted for delivery at the
144 New York–Presbyterian Allen Hospital and Columbia University Irving Medical Center (Sutton
145 et al., 2020).

146 Information on introduced Non-Drug Interventions comes from publicly available sources.

147 Other data sources, such as subpopulation selection, commuting patterns, or air travel flows,
148 used during simulation, are embedded in the GLEAM software and well described by its
149 developers (Van den Broeck et al., 2011).

150 **Model parametrization**

151 Below and in **Table 1**, we present a set of parameters that was used in the model. Most
152 parameters were derived from the literature. In the absence of a reliable reference, the parameters
153 were assigned with the most plausible values by the authors based on the epidemiological
154 knowledge on SARS-CoV-2 and other viruses. The parameters' derivation method is
155 summarized in **Table 1**.

156 The average latency period (*lp*) of 5.6 days is a consensus of different estimations calculated
157 previously (Lauer et al., 2020). Due to 1) long *lp*, effectively much longer than reported for other
158 coronaviruses, and 2) known cases of presymptomatic transmission (Woelfel et al., 2020; Tong
159 et al., 2020), for the modelling purposes we decided to split the latency period into two parts: 1)
160 average latent non-infectious period (*lnip*) of 1.1 days (based on the time of infectivity for other
161 viruses (Wallinga & Teunis, 2004)), and 2) average presymptomatic infectious period (*pip*) of
162 4.5 days. This split produces two parameters used in the model:

163 1) latency rate for the non-infectious period - non-infectious epsilon ($ni\varepsilon$):

$$164 \quad ni\varepsilon = 1/lnip,$$

165 and

166 2) latency rate for the infectious period - latency rate infectious epsilon ($i\varepsilon$):

$$167 \quad i\varepsilon = 1/(lp - lnip).$$

168 As the Republic of Korea provided high quality, reliable data and conducted a large number of
169 tests during the pandemic, we decided to use Korean proportion of “severe” to diagnosed cases
170 as a base for the probability of developing the severe condition (pS), and we set it to 0.01 . We
171 assumed that patients with mild symptoms, in contrast to those in severe condition, are still
172 capable of travelling. For model simplicity, we decided to merge into one compartment all mild
173 and asymptomatic cases.

174

175 We decided to set the probability of detection of severe infection (pDS) to 0.6 , in order to mimic
176 two obstacles, typically preventing proper accurate diagnosis. Firstly, the majority of patients
177 with a severe course of the disease are either chronically ill or above 60 (Zhou et al., 2020) -
178 their symptoms might be mistaken with those caused by their general health condition, and thus
179 not reported on time. Secondly, the model is supposed to reflect the average illness detection
180 around the globe, which includes many countries with low quality or underfinanced healthcare,
181 where the number of SARS-CoV-2 tests is very limited.

182

183 Another parameter of the model, pDM is the probability of being diagnosed with COVID-19
184 when having either mild symptoms or an asymptomatic illness course. This parameter depends
185 on previously defined pS and pDS , as well as the ratio of total diagnosed to undiagnosed cases
186 (tDR):

$$187 \quad pDM = (tDR - pS * pDS) \div (1 - pS).$$

188 Knowing the limitations of previous modelling attempts (Cowling et al.; Ganyani et al., 2020;
189 Zhang et al., 2020; Chen et al., 2020; Wu, Leung & Leung, 2020; Lin et al., 2020; Kucharski et
190 al., 2020), we decided to test a radically different COVID-19 epidemiologic paradigm, i.e. a
191 significantly lower tDR . It means that in our model, we assume a higher proportion of undetected
192 cases in comparison to other models proposed so far. Taking into account that none of them was
193 capable of providing a plausible global simulation of the pandemic, plus the fact that the
194 potentially low detectability has already been discussed in the literature (Nishiura et al., 2020; Li
195 et al., 2020a; Day, 2020a,b; Kimball et al., 2020), we decided to test such a possibility in
196 simulation by setting the lowest possible tDR . Its relation to pDM sets its minimum to:

$$197 \quad tDR > pS * pDS.$$

198 For previously set pS and pDS values, tDR must be greater than 0.006 , thus the value used in our
199 simulation was set to 0.0061 . This value means that for 10,000 of COVID-19 cases only 61 are
200 positively diagnosed. The justification for such a strong assumption is based on the following:
201 (i) tDR reflects the average global detectability of the virus, including countries of low quality of
202 public healthcare; (ii) tDR reflects the average detectability of the virus during the entire
203 examined period of 154 days that describes early stages of the pandemic; (iii) the percentage of
204 asymptomatic or atypical cases is currently unknown, but small-scale screening tests conducted
205 so far indicate that even 88% of examined diagnosed cases could be asymptomatic (Sutton et al.,
206 2020); and (iv) some of the currently used tests might be faulty e.g. when viral load is small (Pan
207 et al., 2020).

208

209 Other important and interconnected parameters required by the model are as follows: the
210 effective contact rate, β ; its reduction level for patients who developed severe symptoms of the
211 disease but were not diagnosed, $r\beta$; and average recovery time since symptoms development μ .
212 The parameter β is derived from the time a host remains infectious, d , and the basic reproduction
213 number of the virus, R_0 :

$$214 \quad \beta = R_0 \div d ,$$

215 where:

$$216 \quad d = \mu + pip.$$

217 The estimation of R_0 is a topic widely discussed in the literature, with values ranging from 1.4 to
218 6.49 (“Statement on the second meeting of the International Health Regulations (2005)
219 Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)”); Majumder &
220 Mandl; Zhao et al.; Imai et al., 2020; Read et al., 2020; Liu et al., 2020). However, following the
221 assumption of much higher than the currently suspected ratio of undiagnosed cases, we decided
222 to use in our model a higher rate of transmissibility, yet well within the range of 2-5, modelled
223 for SARS (Wallinga & Teunis, 2004). The R_0 value assumed in our model is 4.4.

224 In our study μ is derived from a safe quarantine period for diagnosed cases (Woelfel et al., 2020).
225 As the safe quarantine time is estimated to be 10 days (Woelfel et al., 2020), we assumed μ to
226 last on average for 7 days from symptoms development to recovery. The sum of μ and
227 previously estimated pip (presymptomatic infectious period) results in d equal to 11.5 days, and
228 β equal to 0.38261.

229 We decided to set $r\beta$ to 0.5, following the assumption for this parameter used in GLEAM
230 modelling of the 2009 influenza outbreak (Balcan et al., 2010). Patients who were diagnosed
231 with COVID-19 are assumed isolated and as such, not spreading the disease any further.

232 **Model compartmentalization**

233 To model the virus spread, we modified the compartmental SIR metapopulation transmission
234 model to represent the nature of the COVID-19 epidemic.

235 In our model, we used seven different compartments (**Figure 1**).

- 236 1. Susceptible population - equal to the general global population. We assume no existing
237 immunity to infection.
- 238 2. Latent non-infectious - infected population in the first incubation stage, not yet infectious.
- 239 3. Presymptomatic infectious - infected population already infectious, but without
240 developed symptoms.
- 241 4. Mild symptoms - joint populations of asymptomatic cases and those with inconspicuous
242 symptoms.
- 243 5. Severe symptoms - population infected by SARS-CoV-2 with symptoms affecting their
244 travel ability.
- 245 6. Diagnosed - population identified as infected with the SARS-CoV-2 virus. This is the
246 reference line for the model accuracy.
- 247 7. Recovered - joint populations of recovered and fatal cases. We assumed recovered
248 individuals cannot be reinfected, although the only evidence so far is for rhesus macaques
249 (Ota, 2020) and WHO is still investigating the issue .

250
251 The last step was necessary to avoid the problem of unknown mortality rate of the virus. It
252 should be noted that the currently reported mortality rate only applies to diagnosed cases (CFR,
253 case fatality ratio), and its value still lacks consensus varying from 0.9%-2.1% (Wu et al., 2020).

254 The true mortality rate (IFR, infected fatality ratio) that takes into account all undiagnosed cases
255 is likely to be much smaller. For China for instance, it has been estimated at 0.66% (Verity et al.,
256 2020). However, even if we assume that we currently detect all COVID-19 cases, it should not
257 exceed 3.4% (WHO estimation) and this already is negligible from the perspective of our model
258 (I.e. artificial increasing of the number of recovered, and thus immune individuals by this
259 amount should not affect the model's final outcome much).

260 **Model running**

261 The prepared model served as an input for 20 runs of GLEAM stochastic simulations. The
262 GLEAM framework uses high-resolution worldwide population data, allowing for the definition
263 of subpopulations according to a Voronoi decomposition of the world surface centered on the
264 locations of International Air Transport Association (IATA)-indexed airports (www.iata.org).
265 Short-range commuting networks for the defined subpopulations are constructed on the basis of
266 data on the commuting patterns of 29 countries in five continents, generalized to a general
267 gravity law for commuting flows, reproducing commuting patterns worldwide.
268 The stochastic simulation of the pandemic was started on Nov 17th, 2019. Although this date is
269 stated only in non-academic sources, other reports also indicate mid-November as the time of the
270 pandemic outbreak (Li et al., 2020b). The simulation began with a single presymptomatic
271 individual located in Wuhan, China, and the development of the pandemic spread was modelled
272 for 154 days.

273 **Model results processing**

274 A single model run yields two sets of results. The first set is the median value and confidence
275 intervals for the number of individuals per thousand which, at a given day, were moved to each
276 of the compartments (presented in **Figure 1**). The second set is the median value and confidence
277 intervals for a cumulative number of individuals per thousand, entering each of the
278 compartments, until a given day. Both sets of results can be extracted with different resolutions -
279 globally, by hemisphere, continent, country, or the tessellated area surrounding IATA-registered
280 airports.

281 For areas selected for detailed analyses of model results (i.e. twenty selected countries and the
282 New York area), a cumulative number of transitions into a compartment of interest (i.e.
283 “Diagnosed” and “Mild symptoms” respectively) was multiplied by the area population, and
284 divided by thousand. The display of the model results was limited to the dates for which the
285 experimentally derived data was available.

286 In order to compare model results with the random screening test from the New York area
287 (Sutton et al., 2020), it was necessary to calculate the average number of undiagnosed mild and
288 asymptomatic cases in this region (c_s) for the period covered by the experiment. The median and
289 the lower and upper confidence limits of the number of individuals entering the “Mild
290 symptoms” compartment at any day (n) of the simulation is provided by the GLEAM framework
291 (c_{p+m}^n , c_{p+l}^n , and c_{p+u}^n , respectively), while the number of individuals leaving the compartment
292 (c_{p-}^n) was estimated similarly as in the framework:

$$293 \quad c_{p-}^n = c_p^n \div \mu,$$

294 where c_p^n stands for the average number of infected but not diagnosed asymptomatic or mild
295 symptoms cases at day n . For each day (n) of the simulation, c_p^n and its lower and upper
296 confidence limits, c_{pl}^n and c_{pu}^n , were calculated as:

$$\begin{aligned} 297 \quad c_p^n &= c_p^{n-1} + c_{p+m}^n - c_p^{n-1}, \\ 298 \quad c_{pl}^n &= c_p^{n-1} + c_{p+l}^n - c_p^{n-1}, \\ 299 \quad c_{pu}^n &= c_p^{n-1} + c_{p+u}^n - c_p^{n-1}. \end{aligned}$$

300 The lower and upper confidence limits for c_s , respectively c_{sl} and c_{su} , used for comparison with
301 confidence interval derived from the screening test, were obtained as:

$$\begin{aligned} 302 \quad c_{sl} &= (\sum_{n=126}^{139} c_{pl}^n) / (139 - 126), \text{ and} \\ 303 \quad c_{su} &= (\sum_{n=126}^{139} c_{pu}^n) / (139 - 126), \end{aligned}$$

304 where $n = 126$ and $n = 139$ stand for simulation steps referring to Mar 22nd, 2020, and Apr 2nd,
305 2020, respectively.

306 The Excel workbook with performed calculations is provided as Supplementary Workbook 1.

307 Results

308 The simulation modelled the pandemic spread for 154 days. The results for all subpopulations
309 around the globe are available in the shared model file (see the **Data Sharing** section below).

310 As overall data on the pandemic dynamics around the globe is likely to be biased by regions,
311 often considerable in size and population, for which official statistics might be inaccurate, we
312 decided not to compare overall model results with global data. Instead, we limited the analysis of
313 results to twenty countries across five continents which are, in our belief: a) divergent in the
314 proportion of the tested population (as reported in <https://ourworldindata.org/coronavirus-testing-source-data>), quality of healthcare, and strength of undertaken preventative measures; b)
315 likely to provide the public with real data. We also compared the model outcome for the New
316 York area subpopulation with the results obtained in a random screening test on women admitted
317 for delivery (Sutton et al., 2020).

318 The obtained 95% confidence intervals of predicted numbers of diagnosed patients were
319 compared with empirical data from twenty countries. In **Figure 2**, we present a percentage
320 difference over time between the number of reported confirmed cases and confidence interval
321 limits for modelled predictions. Positive values state that the model overestimates the number of
322 diagnosed cases; negative values indicate the underestimations of the model; for the observed
323 numbers of diagnosed cases that are within the model's CIs the percentage difference is equal to
324 0. For most of the selected countries, the model predictions fit well to the observed data,
325 especially in the early stages of the pandemic.

326 Additionally, **Figure 3** confronts the number of actual confirmed COVID-19 cases with
327 confidence intervals for the modelled number of diagnosed cases in twenty selected countries
328 from five continents for all 154 days of the simulation. Some countries present epidemic
329 dynamics different from the model. However, the direction of these deviations may be explained
330 by the measures overtaken by their governments, their societal response, or the number of tests
331 carried per million of citizens. To show the possible influence of Non-Drug Interventions, we
332 summarized them and marked the dates of their introduction in the country charts. Even though it
333 is difficult to assess the effectiveness of precautions without detailed reports from the country in
334 question, in some cases they seem to explain the observed discrepancies well. For instance the
335 number of detected cases in Japan, Australia and New Zealand is much smaller than predicted by
336

337 the model, which might be the result of the ban on flights from China introduced at the beginning
338 of February combined with a geographical isolation of these countries. In contrast, most
339 European countries started introducing preventive actions in March and the potential effects are
340 only slightly visible in the last days of simulation. Similarly, the lack of concordance between
341 model and empirical data in the case of the Republic of Korea may also be caused by the
342 introduced precautions. However, in this case the preventive actions were of a different nature
343 and are not shown in the country chart. Namely, the Republic of Korea introduced what was
344 considered one of the largest and best-organised epidemic control programs in the world,
345 consisting of measures to screen and isolate any infected people, as well as track and quarantine
346 those who contacted them (South Korean Ministry of Health and Welfare).

347 Furthermore, the empirical data from the last day of the simulation, Apr 19th, 2020, was
348 juxtaposed with the obtained confidence intervals in a single plot for all countries (**Figure 4**). In
349 this plot the number of detected cases is presented as a percentage of the country population, in
350 order to better show the width of the obtained confidence intervals in relation to the entire
351 country population. From **Figure 4** it is visible that model predictions are generally within the
352 same order of magnitude as the observed data. So are the differences between upper and lower
353 confidence limits.

354 Finally, for the New York area and the time period between March 22nd, 2020 and April 2nd,
355 2020, we compared the model outcome with the results of a random screening test conducted on
356 women admitted for delivery (Sutton et al., 2020). The cited experimental study revealed that out
357 of 214 women tested, 33 were positively diagnosed with COVID-19, of which 4 had mild
358 symptoms and 29 were asymptomatic. Assuming pregnant women are representative of the
359 entire population and omitting severe COVID-19 cases from calculations (given patients in late
360 pregnancy showing severe symptoms would have been admitted to the hospital earlier), the 95%
361 CI for the true population proportion of mild or asymptomatic cases in the New York area,
362 averaged over the examined period, is 0.11 - 0.21. According to our model, in the same area and
363 averaged over the same period, the 95% CI for this proportion is 0.19 - 0.23. Although the
364 predicted CI is not fully enclosed by the CI of the experimental result, their large overlap
365 suggests high quality and accuracy of the model, started 139 days earlier from a single case on
366 the other side of the globe.

367 Altogether, our 154-day long simulations of the pandemic seem to reflect the empirical data well.
368 However, as is in the case of any model, this reflection is not perfect. The main reason for the
369 discrepancies between model predictions and the reported number of COVID-19 cases is the fast
370 governmental responses and early introduced precautions, which significantly influence the pace
371 of the disease spread. Such preventive measures, for instance local flight bans, are not included
372 in our simulations. In fact, the model depicts only the “natural” dynamics of the pandemic in the
373 situation when governments do nothing to stop it. This means that in countries where overtaken
374 actions were fast and effective, the model has a tendency to overestimate the number of detected
375 cases.

376 The second potential reason for the observed discrepancies between model results and empirical
377 data is the increase of the virus detectability in countries where the proportion of tested
378 individuals is larger, leading to higher *tDR* than the one assumed in our model. To check this
379 hypothesis, we calculated 95% confidence intervals for the Spearman correlation coefficient
380 between: a) the cumulative number of conducted tests per capita in a country, and b) the
381 percentage difference between the cumulative number of detected cases and the lower or upper
382 confidence limit of the CIs obtained in the model (i.e. if the model underestimates the number of

383 detected cases, its upper confidence limit is used in calculations, and *vice versa*; if the observed
384 data is within the predictions of the model, the difference is zero). The correlations' CIs were
385 calculated separately for each day of the simulation, if only sufficient data on countries' testing
386 effort were available in the datasource. Missing data on the number of carried tests were
387 interpolated if possible. As some countries started testing earlier than others, the number of
388 datapoints for correlations varies from 4 to 18, depending on the date. The obtained CIs for
389 correlations are plotted on a timeline in **Figure 5**. It is visible that within the used data and with a
390 limited sample size of 4 to 18 countries, it is not possible to state the direction of the correlation
391 and decide if the tested hypothesis is true.

392 We believe that further modelling efforts, that will include careful parameters' modifications
393 over time in order to better reflect local responses to the pandemic, would greatly improve the
394 accuracy of the simulations, but it is outside of the scope of this work.

395 **Data sharing**

396 The model and the results of the simulation are freely available at
397 <https://github.com/freesci/covid19>.

398 The data used to generate **Figure 5** is provided as **Supplementary Table 1**.

399 The data and calculations used to obtain confidence intervals for the proportion of the mild and
400 asymptomatic cases in the New York area is provided as **Supplementary Workbook 1**.

401 **Discussion**

402 The presented model, due to its stochastic nature, avoids the problem of biased and inaccurate
403 data and provides simulations of the pandemic spread for all the countries around the globe. It
404 also has multiple implications concerning the major characteristics of the COVID-19 pandemic,
405 such as the basic reproduction number of the virus R_0 (higher than previously assumed, yet not
406 above the values estimated for other coronaviruses), and the average ratio of diagnosed cases
407 tDR (much lower than assumed so far, especially for cases expressing mild symptoms and
408 asymptomatic). Such a low tDR would indicate that the vast majority of the COVID-19
409 infections are so mild that they pass unnoticed. This is not implausible, considering the fact that
410 there are 1.9 billion children aged below 15 years in the world (27% of the global population)
411 and predominantly (ca. 90%) the course of their infections is mild or asymptomatic (Dong et al.,
412 2020). Additionally, the tDR used in our model indicates virus detectability averaged over the
413 entire period of 154 days and over all countries in the world. Furthermore, some COVID-19
414 cases may show atypical symptoms (e.g. diarrhoea) (Gao, Chen & Fang, 2020) which hinder
415 correct diagnosis. Taking all this into account, plus the results of our model and latest reports on
416 the low detectability of the virus (Nishiura et al., 2020; Li et al., 2020a; Day, 2020a,b; Kimball et
417 al., 2020), one may risk a hypothesis that the virus is already more prevalent in the global
418 population than shown in official statistics at the moment, and consequently, its mortality rate is
419 much lower.

420 To verify this hypothesis, further actions are required. At first, the model should be refined by
421 stochastic fitting of parameters to the observed data. Also the sensitivity analysis of the
422 parameters should be performed. Such a refined model could be used for the analysis of the
423 effectiveness of the applied Non-Drug Interventions and possibly, for the modelling of future
424 NDI strategies. Secondly, a simulation with the tDR parameter increasing over time or

425 diverging geographically might better reflect the actual virus detectability in the course of the
426 pandemic.

427 Finally, the real spread of the virus should be assessed empirically by conducting a sufficient
428 number of tests on fully random samples as currently, most tests are limited to individuals with
429 strong and typical symptoms. Only after obtaining a solid measurement of the actual prevalence
430 of the virus, can one draw conclusions about its true mortality rate.

431 We emphasize that our conclusions are a hypothesis based on a single computational model and
432 without empirical verification, but they serve as a platform for further research. At this stage, by
433 no means should they be used as a reason for governmental decisions on lifting the precautions.
434 Even if the true mortality of the virus is indeed lower than announced by the media, to our best
435 knowledge many people remain in the high-risk group (e.g elderly, chronically ill, etc. (Baud et
436 al., 2020)). Lack of population resistance facilitates their contact with the virus and may lead to a
437 rapid increase of severe cases in a short time, as seen for example in Italy (Remuzzi & Remuzzi,
438 2020), leading to the collapse of the healthcare system, which affects the entire society and
439 results in many additional deaths not related to the virus itself. Careful use and tuning of Non-
440 Drug Interventions, constant balancing of the disease spread and healthcare capacity, protecting
441 the most vulnerable individuals, farsighted anticipation and agility in decision making may
442 altogether be able to minimize the number of deaths without resulting in the global economic
443 breakdown.

444 **Conclusions**

445 Our model implies that the current consensus on the basic reproduction number of SARS-CoV-2
446 and its prevalence are misestimated. The overall global data on the pandemic dynamics seems
447 strongly biased by large regions where official statistics may not reflect accurately the state of
448 the epidemic, and by the fact that many COVID-19 cases may go unnoticed. The basic
449 reproduction rate of the virus should be confirmed based on reliable data, and its prevalence
450 determined by conducting properly designed screening tests.

451 **References**

- 452 Balcan D, Gonçalves B, Hu H, Ramasco JJ, Colizza V, Vespignani A. 2010. Modeling the spatial spread
453 of infectious diseases: the GLObal Epidemic and Mobility computational model. *Journal of*
454 *computational science* 1:132–145.
- 455 Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. 2020. Real estimates of mortality
456 following COVID-19 infection. *The Lancet infectious diseases*. DOI: 10.1016/S1473-
457 3099(20)30195-X.
- 458 Chen T-M, Rui J, Wang Q-P, Zhao Z-Y, Cui J-A, Yin L. 2020. A mathematical model for simulating the
459 phase-based transmissibility of a novel coronavirus. *Infectious diseases of poverty* 9:24.
- 460 Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, Liao Q, Kwan MYW, Lee SL, Chiu SS,

- 461 Wu JT, Wu P, Leung GM. Impact assessment of non-pharmaceutical interventions against COVID-
462 19 and influenza in Hong Kong: an observational study. DOI: 10.1101/2020.03.12.20034660.
- 463 Day M. 2020a. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian
464 village. *BMJ* 368:m1165.
- 465 Day M. 2020b. Covid-19: four fifths of cases are asymptomatic, China figures indicate. *BMJ* 369:m1375.
- 466 Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time.
467 *The Lancet infectious diseases*. DOI: 10.1016/S1473-3099(20)30120-1.
- 468 Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. 2020. Epidemiological Characteristics of 2143
469 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics*. DOI: 10.1542/peds.2020-
470 0702.
- 471 Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, Hens N. 2020. Estimating the generation
472 interval for COVID-19 based on symptom onset data. *medRxiv*.
- 473 Gao QY, Chen YX, Fang JY. 2020. 2019 Novel coronavirus infection and gastrointestinal tract. *Journal*
474 *of digestive diseases*. DOI: 10.1111/1751-2980.12851.
- 475 Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, Ferguson NM. 2020. Report 3:
476 transmissibility of 2019-nCoV. *Reference Source*.
- 477 Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S,
478 Chisty Z, Bell JM, Methner M, Harney J, Jacobs JR, Carlson CM, McLaughlin HP, Stone N, Clark
479 S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Russell D, Hiatt B, Gant J, Duchin JS, Clark TA,
480 Honein MA, Reddy SC, Jernigan JA, Public Health – Seattle & King County, CDC COVID-19
481 Investigation Team. 2020. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents
482 of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. *MMWR*.
483 *Morbidity and mortality weekly report* 69:377–381.
- 484 Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, Eggo RM, Centre for Mathematical
485 Modelling of Infectious Diseases COVID-19 working group. 2020. Early dynamics of transmission
486 and control of COVID-19: a mathematical modelling study. *The Lancet infectious diseases*. DOI:

- 487 10.1016/S1473-3099(20)30144-4.
- 488 Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. 2020.
- 489 The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported
- 490 Confirmed Cases: Estimation and Application. *Annals of internal medicine*. DOI: 10.7326/M20-
- 491 0504.
- 492 Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, Rossi L,
- 493 Manganelli R, Loregian A, Navarin N, Abate D, Sciro M, Merigliano S, Decanale E, Vanuzzo MC,
- 494 Saluzzo F, Onelia F, Pacenti M, Parisi S, Carretta G, Donato D, Flor L, Cocchio S, Masi G, Sperduti
- 495 A, Cattarino L, Salvador R, Gaythorpe KAM, Imperial College London COVID-19 Response Team,
- 496 Brazzale AR, Toppo S, Trevisan M, Baldo V, Donnelly CA, Ferguson NM, Dorigatti I, Crisanti A.
- 497 2020. Suppression of COVID-19 outbreak in the municipality of Vo, Italy.
- 498 *medRxiv:2020.04.17.20053157*.
- 499 Lin Q, Zhao S, Gao D, Lou Y, Yang S, Musa SS, Wang MH, Cai Y, Wang W, Yang L, He D. 2020. A
- 500 conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with
- 501 individual reaction and governmental action. *International journal of infectious diseases: IJID:*
- 502 *official publication of the International Society for Infectious Diseases* 93:211–216.
- 503 Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020a. Substantial undocumented infection
- 504 facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science*. DOI:
- 505 10.1126/science.abb3221.
- 506 Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. 2020. The reproductive number of COVID-19 is higher
- 507 compared to SARS coronavirus. *Journal of travel medicine* 27. DOI: 10.1093/jtm/taaa021.
- 508 Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley BT, Chaillon A. 2020b. Evolutionary history, potential
- 509 intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of medical virology*.
- 510 DOI: 10.1002/jmv.25731.
- 511 Majumder M, Mandl KD. Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China.
- 512 *SSRN Electronic Journal*. DOI: 10.2139/ssrn.3524675.

- 513 Nishiura H, Kobayashi T, Suzuki A, Jung S-M, Hayashi K, Kinoshita R, Yang Y, Yuan B,
514 Akhmetzhanov AR, Linton NM, Miyama T. 2020. Estimation of the asymptomatic ratio of novel
515 coronavirus infections (COVID-19). *International journal of infectious diseases: IJID: official*
516 *publication of the International Society for Infectious Diseases*. DOI: 10.1016/j.ijid.2020.03.020.
- 517 Ota M. 2020. Will we see protection or reinfection in COVID-19? *Nature reviews. Immunology*. DOI:
518 10.1038/s41577-020-0316-3.
- 519 Pan Y, Long L, Zhang D, Yan T, Cui S, Yang P, Wang Q, Ren S. 2020. Potential false-negative nucleic
520 acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation
521 of samples with low viral loads. *Clinical chemistry*. DOI: 10.1093/clinchem/hvaa091.
- 522 Read JM, Bridgen JRE, Cummings DAT, Ho A, Jewell CP. 2020. Novel coronavirus 2019-nCoV: early
523 estimation of epidemiological parameters and epidemic predictions. *medRxiv*.
- 524 Remuzzi A, Remuzzi G. 2020. COVID-19 and Italy: what next? *The Lancet* 395:1225–1228.
- 525 South Korean Ministry of Health and Welfare. Coronavirus disease 19(COVID-19). *Available at*
526 *<http://ncov.mohw.go.kr/en/>* (accessed April 25, 2020).
- 527 Statement on the meeting of the International Health Regulations (2005) Emergency Committee regarding
528 the outbreak of novel coronavirus 2019 (n-CoV) on 23 January 2020. *Available at*
529 *[https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-](https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))*
530 *[health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-](https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))*
531 *[\(2019-ncov\)](https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))* (accessed April 23, 2020).
- 532 Statement on the second meeting of the International Health Regulations (2005) Emergency Committee
533 regarding the outbreak of novel coronavirus (2019-nCoV). *Available at [https://www.who.int/news-](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))*
534 *[room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))*
535 *[\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))* (accessed
536 March 20, 2020).
- 537 Steven Sanche, Yen Ting Lin, Chonggang Xu, Ethan Romero-Severson, Nick Hengartner, Ruian Ke.
538 2020. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus

- 539 2. *Emerging Infectious Disease journal* 26. DOI: 10.3201/eid2607.200282.
- 540 Streeck H, Hartmann G, Exner M, Schmid M. 2020. Preliminary result and conclusions of the COVID-19
541 case cluster study (Gangelt Municipality). *Available at:*
542 [https://www.land.nrw/sites/default/files/asset/document/zwischenenergebnis_covid19_case_study_gan](https://www.land.nrw/sites/default/files/asset/document/zwischenenergebnis_covid19_case_study_gangelt_en.pdf)
543 [gelt_en.pdf](https://www.land.nrw/sites/default/files/asset/document/zwischenenergebnis_covid19_case_study_gangelt_en.pdf) (accessed April 29, 2020).
- 544 Sutton D, Fuchs K, D’Alton M, Goffman D. 2020. Universal Screening for SARS-CoV-2 in Women
545 Admitted for Delivery. *The New England journal of medicine*. DOI: 10.1056/NEJMc2009316.
- 546 Tizzoni M, Bajardi P, Poletto C, Ramasco JJ, Balcan D, Gonçalves B, Perra N, Colizza V, Vespignani A.
547 2012. Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm.
548 *BMC medicine* 10:165.
- 549 Tong Z-D, Tang A, Li K-F, Li P, Wang H-L, Yi J-P, Zhang Y-L, Yan J-B. 2020. Potential
550 Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging*
551 *infectious diseases* 26. DOI: 10.3201/eid2605.200198.
- 552 Van den Broeck W, Gioannini C, Gonçalves B, Quagiotto M, Colizza V, Vespignani A. 2011. The
553 GLEaMviz computational tool, a publicly available software to explore realistic epidemic spreading
554 scenarios at the global scale. *BMC infectious diseases* 11:37.
- 555 Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H,
556 Walker P, Fu H, Dighe A, Griffin J, Cori A, Baguelin M, Bhatia S, Boonyasiri A, Cucunuba ZM,
557 Fitzjohn R, Gaythorpe KAM, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S,
558 van-Elsand S, Volz E, Wang H, Wang Y, Xi X, Donnelly C, Ghani A, Ferguson N. 2020. Estimates
559 of the severity of COVID-19 disease. *medRxiv:2020.03.09.20033357*.
- 560 Wallinga J, Teunis P. 2004. Different epidemic curves for severe acute respiratory syndrome reveal
561 similar impacts of control measures. *American journal of epidemiology* 160:509–516.
- 562 Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, Niemeyer D, Vollmar P,
563 Rothe C, Hoelscher M, Others. 2020. Clinical presentation and virological assessment of
564 hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. *medRxiv*.

565 Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, Cowling BJ, Lipsitch M, Leung
566 GM. 2020. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan,
567 China. *Nature medicine* 26:506–510.

568 Wu JT, Leung K, Leung GM. 2020. Nowcasting and forecasting the potential domestic and international
569 spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet*
570 395:689–697.

571 Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. 2020. Estimation of the reproductive number of novel
572 coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A
573 data-driven analysis. *International journal of infectious diseases: IJID: official publication of the*
574 *International Society for Infectious Diseases* 93:201–204.


575 Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, Lou Y, Gao D, Yang L, He D, Wang MH.
576 Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in
577 China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. DOI:
578 10.1101/2020.01.23.916395.

579 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X,
580 Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk factors for mortality of adult
581 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. DOI:
582 10.1016/S0140-6736(20)30566-3.

583

584

585




586

587 *Figure 1: Structure of compartments used in modelling.*

588 A susceptible individual in contact with a person: 1) presymptomatic, 2) who developed mild
 589 symptoms, or 3) who developed severe symptoms, may contract the infection at rate β , β or $r\beta^*\beta$,
 590 respectively, and enter the latent non-infectious compartment where he is infected but not yet
 591 infectious. During the non-infectious period, each individual has a probability of $ni\epsilon$ of becoming

592 presymptomatic infectious. The presymptomatic cases have probability $i\varepsilon$ of developing severe
593 or mild COVID-19 symptoms, with probabilities pS and $1-pS$, respectively. The transition from
594 both symptomatic groups occurs at μ rate. Individuals who developed severe symptoms do not
595 travel within and between modelled subpopulations and may be either diagnosed with probability
596 pDS , or recover with probability of $1-pDS$. Individuals whose mild (or non-existent) symptoms
597 are not stopping them from traveling may be diagnosed with probability pDM or recover with
598 probability $1-pDM$. The diagnosed individuals are considered isolated and effectively non-
599 contagious and recover with rate μ . The recovery does not discriminate between true recovery
600 and fatal cases.
601

602




603

604
605
606
607
608
609
610
611
612
613
614

Figure 2: Percentage difference over time between the number of reported cases and confidence intervals' limits for modelled predictions.
Positive values state that the model overestimates the number of diagnosed cases, negative values indicate the underestimations of the model. Observed numbers of cases that are within the model CIs are equal to 0. For clarity, country plots were grouped by continents and presented in five plots: **A:** Asia, **B:** Europe, **C:** North America, **D:** South America, **E:** Australia and Oceania. The large discrepancies for Japan, Australia, New Zealand and the Republic of Korea are putatively caused by the fast and pronounced reaction of their governments and early introduced NDIs which are not reflected in our model.

615
616




617

618
619
620
621
622
623
624
625
626
627
628
629
630

*Figure 3: An overlay of modelled confidence intervals for the predicted cumulative number of diagnosed cases and the actual reported values shown for twenty selected countries. The y-axes show the absolute number of diagnosed cases and due to different country populations are not unified. To facilitate comparisons a blue, dotted line was added as a reference indicating the 0.61% of the total population of a country. This value is the same as the **tDR** parameter used in our model reflecting the assumed ratio of detected to undetected cases. The confidence intervals obtained in our model will approach this value asymptotically. For most countries, observations agree well with model predictions. The observed discrepancies are most likely due to introduced NDIs which are not included in our model. The precautions were categorized and the dates of their introductions were marked on the plots with vertical lines, however, the assessment of their effectiveness is beyond the scope of this research.*


631
632



633
634
635
636
637
638
639
640
641

Figure 4: An overlay of modelled confidence intervals with the empirical data on the number of diagnosed cases for the last day of the simulation, Apr 19th, 2020. The cumulative number of diagnosed cases is presented as a percentage of the country population, facilitating comparisons between countries. Model predictions are generally within the same order of magnitude as the observed data and obtained CIs are relatively narrow despite a limited number of iterations (20).

642



643

644

645 *Figure 5: Correlation between presented model accuracy and per-country testing effort.*

646 An overlay of 95% confidence intervals for the Spearman correlation coefficients between: 1)

647 the interpolated, cumulative number of conducted tests per capita in a country, and 2)

648 the percentage difference between the actual number of detected cases and the lower or upper

649 confidence limit of the CIs obtained in the model. The correlations were calculated separately for

650 each day of the simulation if only sufficient data on testing effort is available. As some countries

651 started testing earlier than others, the number of data points for correlations varies from 4 to 18,

652 depending on the date. The width of the obtained CIs and the values of their limits indicate that

653 with the available data it is not possible to state the direction of the analyzed correlations.

654

655

656

Parameter	Value	Description	Source/Derivation
R_0	4.4	Reproduction number for SARS-CoV-2	Literature-based: assumed on the basis of infectivity rates of other coronaviruses.
μ	7 days	Average recovery time since symptoms development	Literature-based
β	0.38261	Transmission rate	$\mu \div R_0$
$r\beta$	0.5	Reduction in transmission rate resulting from the undiagnosed development of severe COVID-19 symptoms	Literature-based
lp	5.6 days	Average latency period	Literature-based
$lnip$	1.1 days	Average latent non-infectious period	Literature-based: assumed on basis of non-infectious period of Influenza A/H1N1
pip	4.5 days	Average presymptomatic infectious period	$lp - lnip$
$ni\varepsilon$	0.9(09)	Probability of transition from $lnip$ to pip state	$1 \div lnip$
$i\varepsilon$	0.2(2)	Probability of transition from presymptomatic to symptomatic state	$1 \div (lp - lnip)$
pS	0.01	Probability of developing severe COVID-19 symptoms	Literature-data: The most often reported ratio of severe to mild symptoms
pDS	0.6	Probability of being diagnosed when expressing severe COVID-19 symptoms	Assumed, taking into account that: 1. In elderly patients, COVID may be easily misdiagnosed, 2. Most of the countries in the world do not have sufficiently efficient healthcare systems.
tDR	0.0061	Rate of diagnosed SARS-CoV-2 infected individuals	Value representing the smallest possible detectability $> pS * pDS$
pDM	0.00(01)	Probability of being diagnosed when presenting mild or none COVID-19 symptoms	$(tDR - pS * pDS) \div (1 - pS)$

657
658

659 Table 1. List of parameters used for the models and their respective values.